Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
24 05 2022
Historique:
received: 12 11 2021
accepted: 03 01 2022
pubmed: 23 2 2022
medline: 26 5 2022
entrez: 22 2 2022
Statut: ppublish

Résumé

Molecular and cytogenetic studies are essential for diagnosis and prognosis in patients with myelodysplastic syndromes (MDSs). Cell-free DNA (cfDNA) analysis has been reported to be a reliable noninvasive approach for detecting molecular abnormalities in MDS; however, there is limited information about cytogenetic alterations and monitoring in cfDNA. We assessed the molecular and cytogenetic profile of a cohort of 70 patients with MDS by next-generation sequencing (NGS) of cfDNA and compared the results to sequencing of paired bone marrow (BM) DNA. Sequencing of BM DNA and cfDNA showed a comparable mutational profile (92.1% concordance), and variant allele frequencies (VAFs) strongly correlated between both sample types. Of note, SF3B1 mutations were detected with significantly higher VAFs in cfDNA than in BM DNA. NGS and microarrays were highly concordant in detecting chromosomal alterations although with lower sensitivity than karyotype and fluorescence in situ hybridization. Nevertheless, all cytogenetic aberrations detected by NGS in BM DNA were also detected in cfDNA. In addition, we monitored molecular and cytogenetic alterations and observed an excellent correlation between the VAFs of mutations in BM DNA and cfDNA across multiple matched time points. A decrease in the cfDNA VAFs was detected in patients responding to therapy, but not in nonresponding patients. Of note, cfDNA analysis also showed cytogenetic evolution in 2 nonresponsive cases. In summary, although further studies with larger cohorts are needed, our results support the analysis of cfDNA as a promising strategy for performing molecular characterization, detection of chromosomal aberrations and monitoring of patients with MDS.

Identifiants

pubmed: 35192693
pii: 484106
doi: 10.1182/bloodadvances.2021006565
pmc: PMC9131900
doi:

Substances chimiques

Cell-Free Nucleic Acids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3178-3188

Informations de copyright

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Mutat Res. 1995 Oct;338(1-6):107-13
pubmed: 7565866
Clin Chem. 2002 Mar;48(3):421-7
pubmed: 11861434
Appl Transl Genom. 2015 Oct 17;7:19-25
pubmed: 27054081
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Blood. 2018 Oct 18;132(16):1657-1663
pubmed: 30185432
Hematol Oncol. 2019 Oct;37(4):531-533
pubmed: 31291480
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Nat Commun. 2018 Nov 29;9(1):5068
pubmed: 30498206
Haematologica. 2001 Jan;86(1):71-7
pubmed: 11146574
Blood Adv. 2020 Apr 28;4(8):1670-1677
pubmed: 32324887
Haematologica. 2021 Sep 30;:
pubmed: 34587721
Blood. 2017 Mar 23;129(12):1685-1690
pubmed: 28126926
Leuk Lymphoma. 1990;2(6):415-8
pubmed: 27457046
Leuk Res. 2012 Jul;36(7):832-40
pubmed: 22537394
Bioinformatics. 2019 Apr 15;35(8):1299-1309
pubmed: 30192920
BMC Bioinformatics. 2015 Jan 28;16:17
pubmed: 25626454
Cancers (Basel). 2021 Apr 18;13(8):
pubmed: 33919541
Biochem Biophys Res Commun. 2012 Mar 23;419(4):662-9
pubmed: 22382018
Cell. 2016 Jan 14;164(1-2):57-68
pubmed: 26771485
Blood. 2019 Jun 20;133(25):2682-2695
pubmed: 30936070
Br J Haematol. 2021 Jan;192(2):300-309
pubmed: 32945548
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Cancer Sci. 2016 Sep;107(9):1329-37
pubmed: 27323954
Blood Adv. 2018 Nov 27;2(22):3404-3410
pubmed: 30482770
Am J Hematol. 2013 Oct;88(10):831-7
pubmed: 23760779
Am J Hematol. 2018 Jun;93(6):E152-E154
pubmed: 29575088
Nat Genet. 2016 Oct;48(10):1273-8
pubmed: 27571261
Genet Test Mol Biomarkers. 2016 Jul;20(7):341-5
pubmed: 27248906
Blood. 2017 Jun 22;129(25):3371-3378
pubmed: 28424163
Br J Haematol. 2002 Mar;116(4):817-25
pubmed: 11886386

Auteurs

Nieves Garcia-Gisbert (N)

Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Pompeu Fabra University, Barcelona, Spain.

Sara Garcia-Ávila (S)

Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Department of Hematology, Hospital del Mar, Barcelona, Spain.

Brayan Merchán (B)

Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Marta Salido (M)

Group of Translational Research on Hematological Neoplasms, IMIM, Barcelona, Spain; and.
Department of Pathology, and.

Concepción Fernández-Rodríguez (C)

Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Department of Pathology, and.

Joan Gibert (J)

Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Lierni Fernández-Ibarrondo (L)

Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Pompeu Fabra University, Barcelona, Spain.

Laura Camacho (L)

Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Department of Pathology, and.

Marta Lafuente (M)

Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Pompeu Fabra University, Barcelona, Spain.

Raquel Longarón (R)

Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Department of Pathology, and.

Blanca Espinet (B)

Group of Translational Research on Hematological Neoplasms, IMIM, Barcelona, Spain; and.
Department of Pathology, and.

Patricia Vélez (P)

Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Department of Hematology, Hospital del Mar, Barcelona, Spain.

Ramon M Pujol (RM)

Department of Dermatology, Hospital del Mar, Barcelona, Spain.

Marcio Andrade-Campos (M)

Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Leonor Arenillas (L)

Group of Translational Research on Hematological Neoplasms, IMIM, Barcelona, Spain; and.
Department of Pathology, and.

Antonio Salar (A)

Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Department of Hematology, Hospital del Mar, Barcelona, Spain.

Xavier Calvo (X)

Group of Translational Research on Hematological Neoplasms, IMIM, Barcelona, Spain; and.
Department of Pathology, and.

Carles Besses (C)

Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Beatriz Bellosillo (B)

Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Pompeu Fabra University, Barcelona, Spain.
Department of Pathology, and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH